期刊
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
卷 10, 期 2, 页码 127-135出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1756285616677005
关键词
Botox (R); botulinum neurotoxin; chronic daily headache; chronic migraine; onabotulinumtoxinA
Chronic migraine (CM) is a severely disabling neurological condition characterized by episodes of pulsating unilateral or bilateral headache. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox (R)) for the prophylactic treatment of CM in 2010. It has been shown that onabotulinumtoxinA is effective in the reduction of headache frequency and severity in patients with CM. Treatment is well tolerated by the patients. This review reports on the history of botulinum neurotoxin (BoNT) in CM and presents the current clinical evidence for the use of onabotulinumtoxinA in the treatment of CM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据